Prosecution Insights
Last updated: November 04, 2026
Application No. 18/289,032

PEPTIDE-FC FUSIONS FOR TREATING AMYLOID DISORDERS

Final Rejection §112
Filed
Oct 31, 2023
Priority
May 05, 2021 — provisional 63/184,682 +2 more
Examiner
CHERNYSHEV, OLGA N
Art Unit
1675
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Attralus Inc.
OA Round
2 (Final)
54%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
88%
With Interview

Examiner Intelligence

Grants 54% of resolved cases
54%
Career Allowance Rate
525 granted / 963 resolved
-5.5% vs TC avg
Strong +34% interview lift
Without
With
+34.0%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
64 currently pending
Career history
1017
Total Applications
across all art units

Statute-Specific Performance

§101
15.7%
-24.3% vs TC avg
§103
8.4%
-31.6% vs TC avg
§102
11.6%
-28.4% vs TC avg
§112
47.2%
+7.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 963 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Response to Amendment 1. Claims 1, 27, 28 and 31 have been amended, claims 2, 3, 17-20 and 23 canceled and claims 45 and 46 added as requested in the amendment filed on October 06, 2026. Following the amendment, claims 1, 4-7, 9-12, 15, 21, 24, 26-29, 31, 33, 37, 40, 41, 45 and 46 are pending in the instant application. 2. Claims 33, 37, 40 and 41 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention(s), there being no allowable generic or linking claim. Election was made without traverse in the reply filed on June 18, 2026. 3. Claims 1, 4-7, 9-12, 15, 21, 24, 26-29, 31, 45 and 46 are under examination in the instant office action. 4. Any objection or rejection of record, which is not expressly repeated in this action has been overcome by Applicant’s response and withdrawn. 5. Applicant’s arguments filed on October 06, 2026, have been fully considered but found to be not persuasive for reasons set forth below. New grounds of rejections necessitated by Applicant’s amendment are set forth below as well. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. 6. Claim 15 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 15 recites the limitation "amino acid sequence set forth in SEQ ID NO: 20," 21 and 22 in claim 1, which, as amended, is limited to only SEQ ID NOS: 1-13. There is insufficient antecedent basis for this limitation in the claim. The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. 7. Claims 1, 4-7, 9-11, 12, 21, 24, 26-29 and 31, as amended, and new claims 45 and 46 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement for reasons of record in section 8 of paper mailed on July 06, 2026. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Applicant traverses the rejection on premises that the claims have been amended to be limited to the specific sequences and as such satisfy the written description requirement of 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, pp. 10-11 of the Response. Applicant’s argument has been fully considered but found to be not persuasive for reasons that follow. Claims 1, 4-7, 9-11, 12, 21, 24, 26-29 and 31, 45 and 46 encompass fusion proteins comprising two polypeptides, wherein each polypeptide comprises any peptide comprising the amino acid sequence of SEQ ID NO: 1-13 linked to the C-terminus of a variable Fc domain and wherein the polypeptides are linked via a variable spacer. Moreover, the claims specifically require that the first and second Fc domains satisfy a functional limitation of being capable to form a dimer. Thus, the claims encompass a vast genus of polypeptides with essentially endless possibilities to combine the short fragments of the peptides of SEQ ID NO: 1-13 embedded within log stretches of various longer amino acid sequences and inserts of variable domains and spacers, all expected to form dimers. The specification provides selected examples of the fusion proteins that meet the limitations of the claims, but fails to describe the whole genus, as currently claimed. It is not clear how many species are within the claimed genus, and it is impossible to envision and immediately recognize which polypeptide that has any of the amino acid sequences of SEQ ID NOS: 1-13 embedded within its structure is part of Applicant’s invention. The Examiner maintains that in the absence of sufficient recitation of distinguishing identifying characteristics of the claimed fusion proteins, the specification does not provide adequate written description of the claimed genus, and the rejection is maintained. Conclusion 8. No claim is allowed. 9. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to OLGA N CHERNYSHEV whose telephone number is (571)272-0870. The examiner can normally be reached 9AM to 5:30PM, Monday to Friday. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Stucker can be reached at (571)272-0911. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /OLGA N CHERNYSHEV/ Primary Examiner, Art Unit 1675 October 28, 2026
Read full office action

Prosecution Timeline

Oct 31, 2023
Application Filed
Jul 06, 2026
Non-Final Rejection mailed — §112
Oct 06, 2026
Response Filed
Oct 30, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12775008
BIOMARKERS FOR THE PREDICTION AND IDENTIFICATION OF PARKINSON'S DISEASE
4y 5m to grant Granted Oct 27, 2026
Patent 12774321
Anti-Alpha-Synuclein Monoclonal Antibodies, and Methods Using Same
4y 5m to grant Granted Oct 27, 2026
Patent 12775004
METHODS OF THERAPEUTIC PROGNOSTICATION
4y 2m to grant Granted Oct 27, 2026
Patent 12716893
MATERIALS AND METHODS FOR DETECTING AND TREATING AUTOIMMUNE MOVEMENT DISORDERS
4y 10m to grant Granted Aug 25, 2026
Patent 12710431
DIAGNOSTIC FOR CHILDHOOD RISK OF AUTISM SPECTRUM DISORDER
4y 10m to grant Granted Aug 18, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
54%
Grant Probability
88%
With Interview (+34.0%)
2y 11m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 963 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month